iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV): Price and Financial Metrics ETF

iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV): $0.18

0.01 (-5.16%)

POWR Rating

Component Grades

Buy & Hold

NR

Peer

NR

Add BWV to Watchlist
Sign Up

Category: Large Cap Blend ETFs

Category

C

Ranked


in category

BWV Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market

Current price $0.18 52-week high $1.95
Prev. close $0.19 52-week low $0.18
Day low $0.18 Volume 534,200
Day high $0.20 Avg. volume 795,235
50-day MA $0.32 Dividend yield N/A
200-day MA $0.79

BWV Stock Price Chart Interactive Chart >


iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV) ETF Bio


The investment objective of the iPath CBOE S&P 500 BuyWrite ETN is to provide investors with exposure to the CBOE S&P 500 BuyWrite Index. The Index is designed to measure the total rate of return on a hypothetical "buy-write”, or "covered call", strategy on the S&P 500® Index. This strategy consists of a hypothetical portfolio consisting of a "long” position indexed to the S&P 500 Index and the sale of a succession of a one-month, at-the-money S&P 500® call options that are listed on the Chicago Board Options Exchange.

BWV ETF Info

Issuer
Expense Ratio %
Asset Class
Sector Large Cap Blend ETFs
Assets Under Management (AUM) N/A
Net Asset Value (NAV) $0.00
Options? No
Total Holdings N/A

BWV Top Holdings

Symbol Company % of Total

Latest BWV News From Around the Web

Below are the latest news stories about ONCONETIX INC that investors may wish to consider to help them evaluate BWV as an investment opportunity.

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer, Dr. Neil Campbell. To Our Valued Shareholders, As 2023 draws to a close, I am eager to share with you the significant strides Onconetix, Inc. (formerly Blue Water Biotech, Inc.) has made in our journey towards becoming a leader in oncology. This past quarter has been transformative, marked by strategi

Yahoo | December 19, 2023

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancerCINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the “Transaction”), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on

Yahoo | December 18, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning!

William White on InvestorPlace | November 2, 2023

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

Transaction will Advance Company’s Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership TeamCINCINNATI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”), today announced the execution of a non-binding term sheet regarding the acquisition of a private commercial stage oncology biotechnology company (the “Proposed Transaction”). This latest announcement is part of the Company’s new business strategy focusing on

Yahoo | November 2, 2023

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1) (the "Rule"). The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (SEC). On October 20, 2023, BWB filed its Fo

Yahoo | November 1, 2023

Read More 'BWV' Stories Here

BWV Price Returns

1-mo N/A
3-mo N/A
6-mo -46.90%
1-year -81.95%
3-year N/A
5-year N/A
YTD N/A
2023 0.00%
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!